Roche completes tender offer for 89bio, taking control of pegozafermin

Roche/Pegozafermin

Roche's subsidiary accepted all 89bio shares tendered by the 29 October 2025 deadline, about 60.5% of the company, at $14.50 in cash plus the contingent value right. A follow-on merger without a shareholder vote makes 89bio a wholly owned Roche subsidiary and removes it from Nasdaq.

• About 94.1 million shares tendered.
• Phase 3 ENLIGHTEN-Fibrosis (~1,050 patients) reads out first in H1 2027; ENLIGHTEN-Cirrhosis (~760) in 2028.